Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : SARS - what next? -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (667)	8/18/2003 6:05:30 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 1070

Henry, I'm interested in the proportions of those infected, not those who develop pneumonia. That will define the likely outcome when the infection has run its course through the human population. I also like actual viral tests, not symptomatic and geographic definitions of a disease. To specify a disease as sars because somebody has been to Hong Kong Amoy Gardens, but exclude it if there's no geographic link seems odd to me. I suppose they had no test at the time so couldn't define the disease in any other way. But to track the disease, the actual bug and its morphology needs to be studied. They seem to be getting better at knowing whether the bug is present or not. How long do you think sars antibodies will stay in somebody? Would that immunity give them some immunity to a somewhat changed sars bug next time around? Thanks for your information and best wishes with documenting the sars disaster - and hopefully helping defeat it. Mqurice